<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018417</url>
  </required_header>
  <id_info>
    <org_study_id>2019-005</org_study_id>
    <nct_id>NCT04018417</nct_id>
  </id_info>
  <brief_title>Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.</brief_title>
  <official_title>A Randomized, Double-masked, Placebo-controlled Study of the Safety of Amphotericin 0.255 μg/mL in Optisol-GS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornea Research Foundation of America</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Research Foundation of America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the increasing popularity of endothelial keratoplasty, a coincident increase in the rate
      of fungal infections post-keratoplasty has been seen in the United States. In this study, the
      eye bank will harvest pairs of donor corneas and randomize one cornea from each pair to be
      stored in Optisol-GS per Eye Bank Association of America guidelines. The eye bank will add
      amphotericin B 0.255 μg/mL (antifungal) to the storage solution for the mate cornea. The
      study donor corneas will be assigned to participants who are scheduled to undergo Descemet
      membrane endothelial keratoplasty. The surgeons, participants, and evaluators will remain
      masked regarding the donor cornea storage solution assignment. The participants will be
      followed for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Reconsidered significance in light of newly published in vitro data.
  </why_stopped>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial cell density</measure>
    <time_frame>6 months</time_frame>
    <description>Central corneal endothelial cell density will be assessed by specular microscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-keratoplasty fungal keratitis</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of post-keratoplasty fungal keratitis will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Amphotericin B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
    <description>Drug concentration: 0.255 μg/mL</description>
    <arm_group_label>Amphotericin B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age and any race or ethnicity

          -  Scheduled to have Descemet membrane endothelial keratoplasty

        Exclusion Criteria:

          -  History of glaucoma surgery in operative eye

          -  Known allergy or intolerance to amphotericin B

          -  Presence of anterior chamber intraocular lens

          -  Corneal stromal or epithelial dysfunction

          -  Presence of glaucoma defined as optic nerve damage as confirmed on Humphrey visual
             field testing or retinal nerve fiber layer analysis

          -  Presence of peripheral anterior synechiae
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aldave AJ, DeMatteo J, Glasser DB, Tu EY, Iliakis B, Nordlund ML, Misko J, Verdier DD, Yu F. Report of the Eye Bank Association of America medical advisory board subcommittee on fungal infection after corneal transplantation. Cornea. 2013 Feb;32(2):149-54. doi: 10.1097/ICO.0b013e31825e83bf.</citation>
    <PMID>23051906</PMID>
  </reference>
  <reference>
    <citation>Armitage WJ. Preservation of Human Cornea. Transfus Med Hemother. 2011;38(2):143-147. Epub 2011 Mar 16.</citation>
    <PMID>21566714</PMID>
  </reference>
  <reference>
    <citation>Hassan SS, Wilhelmus KR; Medical Review Subcommittee of the Eye Bank Association of America. Eye-banking risk factors for fungal endophthalmitis compared with bacterial endophthalmitis after corneal transplantation. Am J Ophthalmol. 2005 Apr;139(4):685-90.</citation>
    <PMID>15808165</PMID>
  </reference>
  <reference>
    <citation>Hassan SS, Wilhelmus KR, Dahl P, Davis GC, Roberts RT, Ross KW, Varnum BH; Medical Review Subcommittee of the Eye Bank Association of America. Infectious disease risk factors of corneal graft donors. Arch Ophthalmol. 2008 Feb;126(2):235-9. doi: 10.1001/archophthalmol.2007.45.</citation>
    <PMID>18268215</PMID>
  </reference>
  <reference>
    <citation>Keyhani K, Seedor JA, Shah MK, Terraciano AJ, Ritterband DC. The incidence of fungal keratitis and endophthalmitis following penetrating keratoplasty. Cornea. 2005 Apr;24(3):288-91.</citation>
    <PMID>15778600</PMID>
  </reference>
  <reference>
    <citation>Merchant A, Zacks CM, Wilhelmus K, Durand M, Dohlman CH. Candidal endophthalmitis after keratoplasty. Cornea. 2001 Mar;20(2):226-9. Review.</citation>
    <PMID>11248837</PMID>
  </reference>
  <reference>
    <citation>Doshi H, Pabon S, Price MO, Feng MT, Price FW Jr. Overview of Systemic Candida Infections in Hospital Settings and Report of Candida After DMEK Successfully Treated With Antifungals and Partial Graft Excision. Cornea. 2018 Aug;37(8):1071-1074. doi: 10.1097/ICO.0000000000001608.</citation>
    <PMID>29634675</PMID>
  </reference>
  <reference>
    <citation>Duncan K, Parker J, Hoover C, Jeng BH. The Effect of Light Exposure on the Efficacy and Safety of Amphotericin B in Corneal Storage Media. JAMA Ophthalmol. 2016 Apr;134(4):432-6. doi: 10.1001/jamaophthalmol.2016.0008.</citation>
    <PMID>26914028</PMID>
  </reference>
  <reference>
    <citation>Lopez RM, Ayestaran A, Pou L, Montoro JB, Hernandez M, Caragol I. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. Am J Health Syst Pharm. 1996 Nov 15;53(22):2724-7.</citation>
    <PMID>8931814</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

